查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1439091

幽門螺旋桿菌診斷市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按類型、技術、最終用戶、地區和競爭細分

Helicobacter Pylori Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Technology, By End user, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，全球幽門螺旋桿菌診斷市場價值為 5.3152 億美元，預計到 2028 年，預測期內的研究成長將達到 4.25% 的複合CAGR。近年來，幽門螺旋桿菌(H. pylori) 診斷市場出現了顯著成長由於幽門螺旋桿菌感染的盛行率不斷上升，以及人們對其在各種胃腸道疾病（包括消化性潰瘍和胃癌）中的作用的認知不斷提高。幽門螺旋桿菌是一種螺旋形細菌，可感染胃壁，是導致各種消化系統疾病的常見病原體。這種感染主要透過口-口或糞-口途徑傳播，與胃炎、消化性潰瘍有關，嚴重時還會導致胃癌。及時、準確的診斷對於有效管理幽門螺旋桿菌相關疾病至關重要，從而推動了對先進診斷方法的需求。

市場概況
預測期 2024-2028
2022 年市場規模 53152萬美元
2028 年市場規模 67619萬美元
2023-2028 年CAGR 4.25%
成長最快的細分市場 免疫測定
最大的市場 北美洲

由於全球幽門螺旋桿菌感染的高盛行率，全球幽門螺旋桿菌診斷市場正在經歷成長。尤其是新興經濟體，病例激增，創造了巨大的市場需求。尿素呼氣測試和糞便抗原測試等非侵入性診斷方法由於其易於使用和患者舒適度而越來越受歡迎。這些方法正逐漸取代內視鏡檢查等侵入性手術。分子診斷和血清學等診斷技術的進步正在提高幽門螺旋桿菌檢測的準確性和速度。這些發展透過提供更可靠的結果對市場產生積極影響。對即時檢測 (POCT) 設備的需求不斷增加，因為它們可以提供快速的現場結果。這些設備在初級保健機構和資源有限的地區特別有用。

在高感染率、技術進步和對非侵入性檢測的需求不斷成長等因素的推動下，全球幽門螺旋桿菌診斷市場將在未來幾年擴大。然而，市場並非沒有挑戰，包括診斷工具的高成本和抗生素抗藥性。為了抓住機會並應對挑戰，利害關係人必須專注於創新、合作和病患教育，以確保幽門螺旋桿菌相關疾病的早期診斷和有效管理。隨著全球醫療保健格局的不斷發展，幽門螺旋桿菌診斷市場處於持續成長和發展的狀態。

主要市場促進因素

幽門螺旋桿菌感染盛行率上升正在推動全球幽門螺旋桿菌診斷市場

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：全球幽門螺旋桿菌診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依類型（儀器、試劑、服務）
    • 依技術分類（免疫測定、POC、分子診斷）
    • 按最終使用者（醫院和診所、門診護理中心、其他）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖
    • 按類型
    • 依技術
    • 按最終用戶
    • 按地區

第 5 章：亞太地區幽門螺旋桿菌診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 6 章：歐洲幽門螺旋桿菌診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美幽門螺旋桿菌診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：南美洲幽門螺旋桿菌診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲幽門螺旋桿菌診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：市場動態

  • 促進要素
  • 挑戰

第 11 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 12 章：全球幽門螺旋桿菌診斷市場：SWOT 分析

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Thermo Fisher Scientific inc.
  • Biohit Oyj
  • Quest Diagnostics Incorporated
  • Meridian Bioscience
  • Bio-Rad Laboratories
  • Alpha Laboratories Ltd
  • F. Hoffmann-La Roche Ltd
  • Coris BioConcept
  • Certest Biotec
  • Epitope Diagnostics, Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 21969

Global Helicobacter Pylori Diagnostics Market was valued at USD 531.52 Million in 2022 and is anticipated to project study growth in the forecast period with a CAGR of 4.25% through 2028. The Helicobacter Pylori (H. pylori) diagnostics market has witnessed significant growth in recent years due to the rising prevalence of H. pylori infections and the increasing awareness about its role in various gastrointestinal diseases, including peptic ulcers and gastric cancer. Helicobacter pylori is a spiral-shaped bacterium that infects the stomach lining and is a common pathogen responsible for various digestive disorders. The infection is primarily transmitted through oral-oral or fecal-oral routes and is associated with gastritis, peptic ulcers, and in severe cases, stomach cancer. Timely and accurate diagnosis is crucial for the effective management of H. pylori-related conditions, driving the demand for advanced diagnostic methods.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 531.52 Million
Market Size 2028USD 676.19 Million
CAGR 2023-20284.25%
Fastest Growing SegmentImmunoassays
Largest MarketNorth America

The global H. pylori diagnostics market is experiencing growth due to the high prevalence of H. pylori infections worldwide. Emerging economies, in particular, are witnessing a surge in cases, creating a substantial market demand. Non-invasive diagnostic methods such as urea breath tests and stool antigen tests are gaining popularity due to their ease of use and patient comfort. These methods are gradually replacing invasive procedures like endoscopy. Advances in diagnostic technologies, such as molecular diagnostics and serology, are enhancing the accuracy and speed of H. pylori detection. These developments are positively impacting the market by providing more reliable results. The demand for point-of-care testing (POCT) devices is increasing, as they offer rapid and on-the-spot results. These devices are particularly beneficial in primary care settings and resource-limited areas.

The global Helicobacter Pylori diagnostics market is set to expand in the coming years, driven by factors such as high infection rates, technological advancements, and the increasing demand for non-invasive testing. However, the market is not without its challenges, including the high cost of diagnostic tools and antibiotic resistance. To capitalize on the opportunities and address the challenges, stakeholders must focus on innovation, collaboration, and patient education to ensure early diagnosis and effective management of H. pylori-related diseases. As the global healthcare landscape continues to evolve, the H. pylori diagnostics market is positioned for sustained growth and development.

Key Market Drivers

Rising Prevalence of Helicobacter Pylori Infections is Driving the Global Helicobacter Pylori Diagnostics Market

Helicobacter pylori, a spiral-shaped bacterium that infects the human stomach lining, has been recognized as a major global health concern. This microorganism is a primary cause of various gastrointestinal diseases, including peptic ulcers and gastric cancers. The rising prevalence of Helicobacter pylori infections is pushing the global Helicobacter pylori diagnostics market to new heights. Helicobacter pylori infections affect a substantial portion of the global population, with prevalence varying by region. It is estimated that over half of the world's population may be infected with H. pylori. Developing countries often have higher infection rates due to poorer sanitation and healthcare access.

Helicobacter pylori is a primary contributor to various gastrointestinal disorders. It is the leading cause of peptic ulcers, accounting for around 80% of duodenal ulcers and 70% of gastric ulcers. In some cases, untreated infections can lead to severe complications, such as gastrointestinal bleeding and perforation. Perhaps the most concerning consequence of Helicobacter pylori infection is its association with gastric cancer. Long-term infection significantly increases the risk of developing stomach cancer, making it a leading cause of cancer-related deaths worldwide.

The rising prevalence of Helicobacter pylori infections has substantial implications for the global diagnostics market. The surge in Helicobacter pylori infections necessitates more testing to identify individuals at risk. This has boosted the demand for diagnostic tests, including serology, stool antigen tests, and urea breath tests. The growing need for accurate and reliable diagnostics has led to innovations in diagnostic technologies. Molecular testing methods, such as polymerase chain reaction (PCR), have become more widely adopted for their higher sensitivity and specificity. The increasing prevalence of Helicobacter pylori infections and the need for early detection have expanded the global Helicobacter pylori diagnostics market. This has attracted various diagnostic companies and investors to invest in research and development, further driving market growth. Improved healthcare infrastructure and increased awareness about the consequences of Helicobacter pylori infections have also fueled the demand for diagnostics. This, in turn, has made testing more accessible to individuals at risk.

Increased Awareness and Screening Programs is Driving the Global Helicobacter Pylori Diagnostics Market

The increasing recognition of the health hazards linked to H. pylori infections is a major factor propelling the worldwide Helicobacter pylori diagnostics market. Various entities, including governments, healthcare institutions, and advocacy groups, have been proactively advocating for public awareness initiatives to inform people about the possible outcomes of untreated infections. This heightened awareness has encouraged individuals to pursue screening and diagnostic services, thereby amplifying the demand for H. pylori testing. Healthcare providers and public health organizations have initiated screening programs to identify and treat H. pylori infections at an early stage. These programs are especially prevalent in regions with high infection rates, such as Asia, South America, and parts of Europe. In many cases, H. pylori screening is integrated into routine healthcare check-ups, ensuring that individuals are tested and treated as needed. This approach has been vital in reducing the incidence of complications associated with H. pylori infections.

The global Helicobacter pylori diagnostics market has also benefitted from advancements in diagnostic technologies. Traditional methods of detecting H. pylori, such as serology and urea breath tests, have been supplemented by more accurate and efficient methods, including polymerase chain reaction (PCR) and next-generation sequencing (NGS). These technologies enable quicker and more precise diagnosis, leading to better treatment outcomes. Eradicating H. pylori infections can prevent the development of serious gastrointestinal conditions, including ulcers and gastric cancer. As awareness and screening programs have become more effective, the demand for H. pylori diagnostic tests has surged. The rapid identification of H. pylori allows for prompt antibiotic therapy and monitoring of treatment effectiveness, improving patient outcomes and reducing healthcare costs associated with treating complications.

The global Helicobacter pylori diagnostics market has experienced significant growth due to these factors. This growth extends to various segments of the market, including diagnostic tests, endoscopy equipment, and therapeutic regimens. As governments and healthcare providers continue to invest in H. pylori screening programs and the development of more accurate diagnostic tools, the market is expected to expand further. The impact of increased awareness and screening programs is not limited to a specific region. While H. pylori infections are more common in certain parts of the world, the global nature of this bacterium means that efforts to combat it are universal. The ripple effect of reducing H. pylori-related complications is felt in lower healthcare costs, improved quality of life for affected individuals, and a reduced burden on healthcare systems worldwide.

Key Market Challenges

Asymptomatic Carriers and the Need for Widespread Screening

One of the major challenges in the H. pylori diagnostics market is the prevalence of asymptomatic carriers. Many individuals can carry the bacterium without displaying any symptoms, making it difficult to identify them without widespread screening programs. These carriers can unknowingly transmit the infection to others, complicating efforts to control the spread of H. pylori.

Limited Public Awareness

Lack of awareness about H. pylori infection remains a significant issue, particularly in developing countries. Public knowledge about the bacterium, its potential health risks, and the importance of early detection is limited. This lack of awareness impedes efforts to increase demand for diagnostic tests.

Cost and Accessibility

Access to H. pylori diagnostic tests can be a challenge, particularly in low- and middle-income countries. The cost of diagnostic tests, especially the more advanced methods like polymerase chain reaction (PCR) and serology, can be prohibitive for many patients and healthcare systems. The lack of access to affordable diagnostics can delay the early detection and treatment of H. pylori infection.

Variability in Diagnostic Methods

The availability of various diagnostic methods for H. pylori can lead to inconsistent results. These methods include serology, urea breath tests, stool antigen tests, and endoscopy with biopsy. The variability in test results can create confusion among healthcare providers and patients, making it challenging to determine the most appropriate course of treatment.

Antibiotic Resistance

H. pylori is becoming increasingly resistant to antibiotics, which is a growing concern in the medical community. This resistance can complicate treatment regimens and may require additional diagnostic testing to determine the most effective antibiotics to use. These resistance issues may necessitate more advanced diagnostic methods to guide therapy effectively.

Sampling and Testing Challenges

Obtaining a representative sample for H. pylori testing can be challenging, especially when using invasive methods like endoscopy with biopsy. Sampling errors can lead to false negatives, causing delays in diagnosis and treatment. Non-invasive tests like urea breath tests and stool antigen tests can also produce false positives or negatives due to various factors, including patient compliance and the presence of other infections.

Cross-Reactivity with Other Pathogens

Some diagnostic tests for H. pylori may cross-react with other pathogens or substances, leading to inaccurate results. This can create confusion and unnecessary treatment, further emphasizing the need for more specific and reliable diagnostic tools.

Key Market Trends

Technological Advancements

Technological advancements are revolutionizing the healthcare industry, with a particular impact on diagnostics. One notable area where these innovations are making a significant difference is in the diagnosis of Helicobacter pylori (H. pylori) infections. H. pylori is a bacterium that infects the stomach lining and is a common cause of various gastrointestinal diseases, including gastritis and peptic ulcers.

The development of non-invasive diagnostic tests has been a game-changer in the H. pylori diagnostics market. These tests include breath tests and stool antigen tests. Breath tests, such as the urea breath test, are simple and painless, involving the patient breathing into a device that measures the presence of specific compounds produced by H. pylori. Similarly, stool antigen tests detect H. pylori proteins in stool samples. These non-invasive methods are not only more patient-friendly but also highly accurate. Technological advancements in molecular biology have enabled the development of highly sensitive and specific tests for H. pylori. Polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) allow for the detection of H. pylori DNA, offering rapid and precise results. These methods are particularly useful in cases where conventional tests may yield false negatives. Serological tests, which detect the presence of antibodies against H. pylori in the blood, have also seen improvements in accuracy and specificity. Technological innovations in this area have made it easier to differentiate current infections from past exposure, helping clinicians make more informed decisions about treatment. Advances in microfluidics and portable diagnostic devices have led to the development of rapid H. pylori diagnostic tests that can be conducted at the point of care. These POCTs provide real-time results, enabling faster decision-making and reducing the time between diagnosis and treatment initiation.

Segmental Insights

Technology Insights

Based on the category of Technology , Immunoassays emerged as the dominant player in the global market for Helicobacter Pylori Diagnostics in 2022. Immunoassays are a diverse group of diagnostic techniques designed to measure specific antigens (proteins) or antibodies in biological samples. They play a pivotal role in the detection of H. pylori infection by identifying the presence of H. pylori-specific antigens or antibodies in patient samples, such as blood, serum, or stool. Immunoassays are highly accurate and specific, minimizing the chances of false-positive or false-negative results. The use of specific antibodies or antigens ensures that the test correctly identifies the presence or absence of H. pylori. Immunoassays are sensitive enough to detect even low levels of H. pylori antigens or antibodies, making them suitable for early diagnosis and monitoring of infections. Many immunoassays, particularly lateral flow assays, provide rapid results, enabling healthcare providers to make prompt treatment decisions. Immunoassays are generally non-invasive, as they require minimal patient discomfort compared to endoscopy or biopsy methods. This makes them more patient-friendly. Immunoassays are cost-effective, particularly lateral flow assays, which are often less expensive than other diagnostic methods like PCR or endoscopy. Immunoassays are widely accessible and can be used in various healthcare settings, including primary care, clinics, and even at-home test kits.

Type Insights

The Reagents segment is projected to experience rapid growth during the forecast period. Reagent-based diagnostic tests have demonstrated exceptional accuracy and sensitivity in detecting H. pylori infections. They can identify even low levels of the bacterium, which is crucial for both initial diagnosis and monitoring treatment progress. Reagent-based tests, including serology and stool antigen tests, are non-invasive, making them more patient-friendly. Unlike invasive methods like endoscopy, these tests don't require tissue sampling, which can be uncomfortable and carry certain risks. Reagent-based diagnostics tend to be more cost-effective than traditional methods, which involve expensive equipment and skilled medical personnel. This affordability makes it easier to conduct large-scale screening and testing programs. Reagent-based tests provide quicker results, often within hours, allowing healthcare providers to initiate treatment promptly, if necessary, and reducing patient anxiety. The simplicity of reagent-based tests has made them accessible even in remote or resource-limited areas, improving the reach of Helicobacter pylori diagnostics.

Regional Insights

North America emerged as the dominant player in the global Helicobacter Pylori Diagnostics market in 2022, holding the largest market share in terms of value. One of the primary reasons for North America's dominance in the H. pylori diagnostics market is the region's cutting-edge technological advancements in the field of medical diagnostics. The United States and Canada are home to many innovative diagnostic companies, research institutions, and medical professionals. These entities have pioneered the development of highly sensitive and specific diagnostic tests for H. pylori, enabling early detection and better patient outcomes. Advanced diagnostic tools, such as polymerase chain reaction (PCR), serology, and urea breath tests, have been developed and perfected in North America. These techniques provide accurate results and have become the gold standard for H. pylori detection. This technological prowess gives North America a competitive edge in the global market. North America boasts a robust and efficient healthcare infrastructure, which is essential for the successful management and diagnosis of H. pylori infections. This region is known for its well-established healthcare system, including state-of-the-art laboratories, skilled medical professionals, and a vast network of healthcare facilities. The seamless integration of diagnostic services into the existing healthcare system has played a pivotal role in the region's market dominance. In addition, the availability of diagnostic tests across a wide range of healthcare settings, from primary care clinics to specialized gastroenterology centers, ensures that individuals are tested and diagnosed promptly, reducing the overall burden of H. pylori-related diseases.

Key Market Players

Thermo Fisher Scientific inc.

Biohit Oyj

Quest Diagnostics Incorporated

Meridian Bioscience

Bio-Rad Laboratories

Alpha Laboratories Ltd

F. Hoffmann-La Roche Ltd

Coris BioConcept

Certest Biotec

Epitope Diagnostics, Inc.

Report Scope:

In this report, the Global Helicobacter Pylori Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Helicobacter Pylori Diagnostics Market, By Type:

  • Instruments
  • Reagents
  • Services

Helicobacter Pylori Diagnostics Market, By Technology:

  • Immunoassays
  • POC
  • Molecular Diagnostics

Helicobacter Pylori Diagnostics Market, By End user:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Helicobacter Pylori Diagnostics Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Helicobacter Pylori Diagnostics Market.

Available Customizations:

  • Global Helicobacter Pylori Diagnostics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Helicobacter Pylori Diagnostics Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type (Instruments, Reagents, Services)
    • 4.2.2. By Technology (Immunoassays, POC, Molecular Diagnostics)
    • 4.2.3. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2022)
  • 4.3. Market Map
    • 4.3.1. By Type
    • 4.3.2. By Technology
    • 4.3.3. By End user
    • 4.3.4. By Region

5. Asia Pacific Helicobacter Pylori Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Technology
    • 5.2.3. By End user
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Helicobacter Pylori Diagnostics Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Type
        • 5.3.1.2.2. By Technology
        • 5.3.1.2.3. By End user
    • 5.3.2. India Helicobacter Pylori Diagnostics Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Type
        • 5.3.2.2.2. By Technology
        • 5.3.2.2.3. By End user
    • 5.3.3. Australia Helicobacter Pylori Diagnostics Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Type
        • 5.3.3.2.2. By Technology
        • 5.3.3.2.3. By End user
    • 5.3.4. Japan Helicobacter Pylori Diagnostics Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Type
        • 5.3.4.2.2. By Technology
        • 5.3.4.2.3. By End user
    • 5.3.5. South Korea Helicobacter Pylori Diagnostics Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Type
        • 5.3.5.2.2. By Technology
        • 5.3.5.2.3. By End user

6. Europe Helicobacter Pylori Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Technology
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Helicobacter Pylori Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By End user
    • 6.3.2. Germany Helicobacter Pylori Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By End user
    • 6.3.3. Spain Helicobacter Pylori Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By End user
    • 6.3.4. Italy Helicobacter Pylori Diagnostics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Technology
        • 6.3.4.2.3. By End user
    • 6.3.5. United Kingdom Helicobacter Pylori Diagnostics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Technology
        • 6.3.5.2.3. By End user

7. North America Helicobacter Pylori Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Technology
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Helicobacter Pylori Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By End user
    • 7.3.2. Mexico Helicobacter Pylori Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By End user
    • 7.3.3. Canada Helicobacter Pylori Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By End user

8. South America Helicobacter Pylori Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Technology
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Helicobacter Pylori Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By End user
    • 8.3.2. Argentina Helicobacter Pylori Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By End user
    • 8.3.3. Colombia Helicobacter Pylori Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By End user

9. Middle East and Africa Helicobacter Pylori Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Technology
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Helicobacter Pylori Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By End user
    • 9.3.2. Saudi Arabia Helicobacter Pylori Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By End user
    • 9.3.3. UAE Helicobacter Pylori Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By End user

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Helicobacter Pylori Diagnostics Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Thermo Fisher Scientific inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Biohit Oyj
  • 14.3. Quest Diagnostics Incorporated
  • 14.4. Meridian Bioscience
  • 14.5. Bio-Rad Laboratories
  • 14.6. Alpha Laboratories Ltd
  • 14.7. F. Hoffmann-La Roche Ltd
  • 14.8. Coris BioConcept
  • 14.9. Certest Biotec
  • 14.10. Epitope Diagnostics, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer